Law360, New York (April 15, 2005, 12:00 AM ET) -- In a major victory for Eli Lilly & Co., an Indiana federal judge has upheld the patent on the key ingredient on its $4.4 billion-a-year Zyprexa schizophrenia drug.
U.S. District Court Judge Richard Young's decision came down in Lilly's favor on all accounts, leaving in effect a patent on the schizophrenia drug Zyprexa that runs through April of 2011.
The decision to uphold the patent on the key ingredient in Zyprexa is a defeat for Ivax Corp., Dr. Reddy's Laboratories Ltd. and Teva Pharmaceutical Industries Ltd.,...
Judge Upholds Zyprexa Patent
To view the full article, take a free trial now.
